Market Survey on Amyotrophic Lateral Sclerosis Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment 2023 to 2033

<p>The global <strong>Amyotrophic Lateral Sclerosis market</strong> is expected to garner a market value of <strong>US$ 743.90 Million</strong> in 2023 and is expected to accumulate a market value of <strong>US$ 1332.22 Million </strong>by registering a CAGR of<strong> 6%</strong> in the forecast period 2023 to 2033. The growth of the Amyotrophic Lateral Sclerosis market can be attributed to the rising geriatric population, growing awareness about ALS, and increasing incidence rate. The market for Amyotrophic Lateral Sclerosis registered a CAGR of <strong>4%</strong> in the historical period 2017 to 2022.</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Expected Market Value (2023)</th><td>US$ 743.90 Million</td></tr><tr><th scope='row'>Anticipated Forecast Value (2033)</th><td>US$ 1332.22 Million</td></tr><tr><th scope='row'>Projected Growth Rate (2023 to 2033)</th><td>6% CAGR</td></tr></tbody></table><p>Report Scope</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Market Value in 2023</th><td>US$ 743.90 Million</td></tr><tr><th scope='row'>Market Value in 2033</th><td>US$ 1332.22 Million</td></tr><tr><th scope='row'>Growth Rate</th><td>CAGR of 6% from 2023 to 2033</td></tr><tr><th scope='row'>Base Year for Estimation</th><td>2022</td></tr><tr><th scope='row'>Historical Data</th><td>2017 to 2022</td></tr><tr><th scope='row'>Forecast Period</th><td>2023 to 2033</td></tr><tr><th scope='row'>Quantitative Units</th><td>Revenue in USD Million and CAGR from 2023 to 2033</td></tr><tr><th scope='row'>Report Coverage</th><td>Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis</td></tr><tr><th scope='row'>Segments Covered</th><td><ul><li>Treatment</li><li>Distribution Channel</li><li>Region</li></ul></td></tr><tr><th scope='row'>Regions Covered</th><td><ul><li>North America</li><li>Latin America</li><li>Europe</li><li>Asia Pacific</li><li>Middle East and Africa (MEA)</li></ul></td></tr><tr><th scope='row'>Key Countries Profiled</th><td><ul><li>USA</li><li>Canada</li><li>Brazil</li><li>Argentina</li><li>Germany</li><li>UK</li><li>France</li><li>Spain</li><li>Italy</li><li>Nordics</li><li>BENELUX</li><li>Australia &amp; New Zealand</li><li>China</li><li>India</li><li>ASIAN</li><li>GCC&nbsp;Countries</li><li>South Africa</li></ul></td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Mitsubishi Tanabe Pharma Corporation</li><li>Otsuka Pharmaceutical Co., Ltd.</li><li>BrainStorm Therapeutics</li><li>Biogen Inc.</li><li>Corestem</li><li>AB Science</li><li>F.Hoffmann-La Roche AG</li><li>Biohaven Pharmaceutical</li><li>Sun Pharmaceutical</li><li>Ionis Pharmaceuticals, Inc.</li></ul></td></tr><tr><th scope='row'>Customization</th><td>Available Upon Request</td></tr></tbody></table>

<p>全球肌萎缩侧索硬化症市场预计在2023年实现市值达7.439亿美元，并在预测期内（2023年至2033年）以6%的复合年增长率积累至13.3222亿美元。肌萎缩侧索硬化症市场的增长得益于老年人口的增长、对肌萎缩侧索硬化症认识的提高以及发病率的上升。在2017年至2022年这一历史时期，肌萎缩侧索硬化症市场以4%的复合年增长率实现了增长。</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>预计2023年市场价值</th><td>7.439亿美元</td></tr><tr><th scope='row'>预期预测值（2033年）</th><td>13.3222亿美元</td></tr><tr><th scope='row'>预测期内的预期增长率</th><td>2023年至2033年复合年增长率6%</td></tr></tbody></table><p>报告范围</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>2023年市场价值</th><td>7.439亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>13.3222亿美元</td></tr><tr><th scope='row'>增长率</th><td>2023年至2033年复合年增长率6%</td></tr><tr><th scope='row'>估算基准年</th><td>2022年</td></tr><tr><th scope='row'>历史数据</th><td>2017年至2022年</td></tr><tr><th scope='row'>预测期</th><td>2023年至2033年</td></tr><tr><th scope='row'>计量单位</th><td>以百万美元计算的收益和2023年至2033年的复合年增长率</td></tr><tr><th scope='row'>报告覆盖范围</th><td>收益预测、量预测、公司排名、竞争格局、增长因素、趋势和定价分析</td></tr><tr><th scope='row'>涵盖的细分市场</th><td><ul><li>治疗</li><li>分销渠道</li><li>地区</li></ul></td></tr><tr><th scope='row'>涵盖的地区</th><td><ul><li>北美</li><li>拉丁美洲</li><li>欧洲</li><li>亚太地区</li><li>中东及非洲（MEA）</li></ul></td></tr><tr><th scope='row'>概述的关键国家</th><td><ul><li>美国</li><li>加拿大</li><li>巴西</li><li>阿根廷</li><li>德国</li><li>英国</li><li>法国</li><li>西班牙</li><li>意大利</li><li>北欧</li><li>比荷卢</li><li>澳大利亚及新西兰</li><li>中国</li><li>印度</li><li>亚洲</li><li>海湾合作委员会国家</li><li>南非</li></ul></td></tr><tr><th scope='row'>概述的关键公司</th><td><ul><li>三菱田边制药公司</li><li>大塚制药有限公司</li><li>BrainStorm Therapeutics</li><li>Biogen Inc.</li><li>Corestem</li><li>AB Science</li><li>F.Hoffmann-La Roche AG</li><li>Biohaven Pharmaceutical</li><li>Sun Pharmaceutical</li><li>Ionis Pharmaceuticals, Inc.</li></ul></td></tr><tr><th scope='row'>定制服务</th><td>根据需求提供</td></tr></tbody></table>